News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure reports continued pipeline momentum for 6 months ended 30th June 2022
29 September 2022
Molecure announces filing of Clinical Trial Application with Polish regulator for OATD-02, a novel dual arginase inhibitor being developed for the treatment of cancer
11 August 2022
Molecure to regain worldwide rights to dual chitinase inhibitor OATD-01
23 June 2022
OncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021
25 March 2022
OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan
11 March 2022
OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board
31 January 2022